The short version of 脂肪酸侧链 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-26. Anything still debated is marked as such rather than presented as settled.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
The U.S. film industry has a worldwide influence and following. Hollywood, a district in central Los Angeles, the nation's second-most populous city, is also metonymous for the American filmmaking industry. The major film studios of the United States are the primary source of the most commercially successful movies selling the most tickets in the world. Largely centered in the New York City region from its beginnings in the late 19th century through the first decades of the 20th century, the U.S. film industry has since been primarily based in and around Hollywood. Nonetheless, American film companies have been subject to the forces of globalization in the 21st century, and an increasing number of films are made elsewhere. The Academy Awards, popularly known as "the Oscars", have been held annually by the Academy of Motion Picture Arts and Sciences since 1929, and the Golden Globes have been held annually since January 1944. The industry peaked in what is commonly referred to as the "Golden Age of Hollywood", from the early sound period until the early 1960s, with screen actors such as John Wayne and Marilyn Monroe becoming iconic figures. In the 1970s, "New Hollywood", or the "Hollywood Renaissance", was defined by grittier films influenced by French and Italian realist pictures of the post-war period. The 21st century has been marked by the rise of American streaming platforms, which came to rival traditional cinema.
== Similar units == Like chemists, chemical engineers use the unit mole extensively, but different unit multiples may be more suitable for industrial use. For example, the SI unit for volume is the cubic metre, a much larger unit than the commonly used litre in the chemical laboratory. When amount of substance is also expressed in kmol (1000 mol) in industrial-scaled processes, the numerical value of molarity remains the same, as
== Toxicity == The recommended therapeutic dose is 80-100 mg/m2 body area. Optimal dosage is determined based on measurements of unbound platinum concentration following intravenous infusion, combined with rate of creatine clearance as an assessment of renal function using Ishibashi’s formula: DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47 The exact mechanism of uptake into the cell is unknown, with information being considerably less available compared to cisplatin. What is known is that nedaplatin does not interact with the Oct2 or apical multidrug and toxin extrusion transporter (MATE) transporters, potentially explaining the difference in nephrotoxicity due to reduced accumulation in the proximal tubules of the kidney. Toxicogenomics has helped elucidate some of the mechanisms behind nephrotoxicity, where oxidative stress has been shown to deregulate gene expression via Hmox1 and other genes.
Sources: en.wikipedia.org
By 1919, the company was able to commercialize production of citric acid from this source. The company developed expertise in fermentation technology as a result. These skills were applied to the deep-submergence mass production of penicillin, an antibiotic, during World War II in response to the need to treat injured Allied soldiers. The company also embarked on a global soil collection program related to improving production yields of penicillin which ultimately resulted in 135,000 samples. On June 2, 1942, the company incorporated under the Delaware General Corporation Law.
Rashtriya Parivartan Dal (National Transformation Party) is a political party in India led by D. P. Yadav. RPD have 2 seats in UP State Assembly. Party President is D. P. Yadav, Uttar Pradesh State President is Ram Samujh and State Vice President is Abhinav Shukla. Yadav's son, Vikas Yadav, had contested the 2002 Uttar Pradesh state assembly elections and lost. Vikas Yadav stands accused of murder. Ahead of the 2004 Lok Sabha elections Yadav joined the Bharatiya Janata Party. His stay in the party did however become short, due to the overwhelming criticism inside the BJP for accepting him in spite of his criminal record. After being expelled from the BJP, Yadav reconstituted RPD
During the night of 21 February, local sources in Afghanistan reported airstrikes in parts of Nangarhar, Paktika, and Khost provinces. In Nangarhar, strikes were reported in the Bihsud and Khogyani districts, while in Paktika, strikes were reported in the Barmal and Urgun districts. Local sources reported that the airstrikes in Nangarhar's Bihsud district struck a civilian home, trapping 23 people beneath the rubble. Pakistan's Ministry of Information and Broadcasting (MolB) stated that the Pakistani military conducted "intelligence-based selective targeting" of seven terrorist camps and hideouts along the Afghanistan-Pakistan border region. The Taliban claimed that the targets included civilian homes and a religious seminary. In a late-night press release, Pakistani officials confirmed that the Pakistan Air Force (PAF), under the command of Air Chief Marshal Zaheer Ahmad Babar, had carried out airstrikes in Afghanistan. Officials said the strikes were selective and intelligence-based, and targeted seven militant camps and hideouts linked to the Tehrik-i-Taliban Pakistan (TTP) and the Islamic State – Khorasan Province (ISIS–K) near the Afghanistan-Pakistan border. Pakistani officials added that the strikes were conducted as retaliation for recent terror attacks in Islamabad, Bajaur, and Bannu.
=== Anterior abdominal aponeuroses === The anterior abdominal aponeuroses are located just superficial to the rectus abdominis muscle. It has for its borders the external oblique, pectoralis muscles, and the latissimus dorsi.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。